MOLECULAR PROFILING IN LOW-GRADE EC 55 3 specific survival (DSS) was defined as time from date of surgery to date of death from EC, all censored by date of last contact. We validated our data with the open access database of Kandoth et al. by performing KaplanMeier analysis. Method and baseline characteristics can be found in the original article.3 RESULTS Patients In total, 689 patients were available with successful DNA analysis, of whom 296 (42.9%) were excluded based on unknown LN status in FIGO early-stage (Efigure 1 in the Supplement). Baseline characteristics of the included versus excluded patients are shown in Etable 2 in the Supplement. Of the included 393 patients, median age was 64.0 (31.0-86.0) years and median BMI 29.1 (18.0-58.3) kg/m2 (Table 1). Baseline characteristics of the included patients according to the four molecular subgroups are shown in Table 1. Molecular subgroup distribution was as followed: POLE-mutant 8.4% (n=33), MSI 19.8% (n=78), TP53-mutant 18.3% (n=72) and NSMP 53.4% (n=210). Low- and high-grade EC were equally distributed in patients with POLE-mutant and MSI tumors. The majority of patients with TP53-mutant tumors were high-grade EC and the majority of NSMP tumors were low-grade EC. The ECrelated mortality was highest in the TP53-mutant subgroup compared to the other molecular subgroups (45.8% vs. 15.7%, 7.7% and 3.0%).
RkJQdWJsaXNoZXIy MTk4NDMw